Screener
Capricor Therapeutics CAPR Government grants
Government grants at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GovernmentAssistanceLiabilityCurrent.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | March 31, 2026 / (unaudited) | December 31, 2025 | December 31, 2025 |
|---|---|---|---|
| Accounts payable | $3,927,941 | $ | $1,654,754 |
| Accrued expenses | 10,528,351 | 15,557,646 | |
| Lease liabilities, current | 841,135 | 202,376 | |
| CIRM liability, current | 6,339,862 | 6,421,984 | |
| Deferred revenue, current | 12,000,000 | 12,000,000 | |
| TOTAL CURRENT LIABILITIES | 33,637,289 | 35,836,760 | |
| LONG-TERM LIABILITIES | |||
| Lease liabilities, net of current | 13,943,595 | 14,320,389 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's government grants?
- Capricor Therapeutics (CAPR) reported government grants of $6.34M in Q1 2026.
- What does government grants mean?
- This represents the current portion of government assistance or grant funding received in advance of fulfilling specific performance obligations or research milestones. It functions as a deferred revenue account that will be recognized as income once the associated research activities or conditions are satisfied. Monitoring this liability helps investors understand the company's near-term obligations to grant-issuing bodies.
Ask your AI about Capricor Therapeutics's government grants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude